Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New spinout enterprise from Oxford seeks to accelerate evidence based innovation for treatments and services in mental health and dementia.

Cristal Health (established in May 2019) has been developed as a sustainable way to accelerate the UK-CRIS programme. The UK-CRIS network operates a managed service for secure access to one of the world's largest repositories of de-identified patient data relating to mental health and dementia conditions.

 

Cristal Health presents a real opportunity for accelerating and translating new discovery medicine, including prevention and treatment, into better health outcomes for sufferers of mental illness and their families. - Mike Dennis, CEO, Cristal Health

Mike Denis, CEO, Cristal Health, said,

"I'm honoured to be leading the team in the joint partnership between the NHS and academia working with industry using real world health data. We're able to add value by continually enriching the clinical content available to clinicians, researchers and scientists which will truly deliver many more opportunities to predict, identify, prevent or manage mental health conditions in the UK." 

The market for real world evidence and data is projected to grow as organisations seek to reduce costs and time, 

 

The spinning out of remarkable new companies like Cristal Health is great news. It brings in investment which allows for exciting initiatives and innovative activity developed in the NHS and Universities to grow more quickly and become sustainable. Everyone benefits and most importantly our patients. - Professor John Geddes, Head of Department of Psychiatry

Cristal Health will focus on three areas:

• Developing offerings to help in early stage drug discovery, reduce clinical trial costs by 12-30%, support post launch and Phase IV evaluation (i.e. following approval) and pharmacovigilance (safety monitoring).

• Supporting NHS Trusts in generating revenue from increased participation in the global trials market and developing tools that support service reviews through ongoing monitoring

• Supporting academic research by developing tools to support text-mining to create real knowledge from distributed and heterogeneous data

Cristal Health will use any profits generated to re-invest into its core purpose of accelerating improvements in medical research, services and outcomes for patients with a mental illness and/or dementia.

To find out more about Cristal Health contact: CEO, Mike Denis, Mike@cristalhealth.co.uk or CIO David, Newton, David@cristalhealth.co.uk.

 

 

Similar stories

Being "in the zone": how waking activity controls sleep need

Research Highlights

A new study from the Vyazovskiy group suggests that how and where we spend our time while awake impacts how much we need to sleep - it does not only depend on how long we are awake.

New Transatlantic Partnership in Mental Health

Strategic Developments

The new partnership between Oxford Health NHS Foundation Trust, the University of Oxford, the University of Toronto, and the Centre for Addiction and Mental Health (CAMH) in Toronto, will enable the development of key structures to facilitate collaboration.

No Evidence of Increased Risk of Suicide in First Months of Pandemic

Research Highlights

A new observational study is the first to examine suicides occurring during the early phase of the COVID-19 pandemic in multiple countries and finds that suicide numbers largely remained unchanged or declined.

Link between COVID-19 infection and mental health and neurological conditions

Research Highlights

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus.

New research to radically alter our understanding of synaptic development

Research Highlights

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.

Healthy Start, Happy Start Study

Research Highlights

Healthy Start, Happy start is a randomised controlled trial that tested the clinical- and cost-effectiveness of a brief parenting programme - Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD).